Sophia Genetics SA has welcomed Amrita Hospital in Faridabad, India, to its network, enhancing its capabilities in the realm of precision medicine. Amrita Hospital will utilize the SOPHiA DDM™ platform to aid in the diagnosis and treatment of rare disorders and cancers, with a focus on exome, solid tumor, and blood cancer applications. This collaboration will allow Amrita Hospital to perform testing in-house, resulting in faster turnaround times for clinicians and researchers. Dr. Moushumi Suryavanshi, Head of Molecular Biology at Amrita Hospital, emphasized the importance of this partnership in providing advanced Next Generation Sequencing testing. The integration into the SOPHiA GENETICS network will also enable Amrita Hospital to contribute valuable insights from Indian genomic data to a global community. Ricardo Ramos Mendonca Filho, Managing Director of LAPAC at SOPHiA GENETICS, highlighted the mission to democratize data-driven medicine and enhance patient care worldwide through this collaboration.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.